Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson began the rollout of its single-dose Covid-19 shot in the U.S. in early March. Here are some of the recent developments relating to the vaccine.

What's Happening With Johnson & Johnson's Covid-19 Vaccine Rollout?

Emergent BioSolutions

The U.S. government places J&J (JNJ) in charge of Emergent's Baltimore factory. The facility will cease production of AstraZeneca shots.

J&J (JNJ) Gets Full Charge of Emergent COVID-19 Vaccine Plant

AstraZeneca

Johnson & Johnson has been put in charge of COVID-19 vaccine production at a Baltimore plant where 15 million doses were ruined several weeks ago. What Happened: The U.S. Department of Health and Human Services put Johnson & Johnson (NYSE: JNJ) in charge of the Emergent BioSolutions Inc (NYSE: EBS) plant in Baltimore.

US Puts Johnson & Johnson In Charge Of Troubled Vaccine Plant In Baltimore, Removes AstraZeneca

Johnson & Johnson, with the aid of President Joe Biden's administration, has been put in charge of a Baltimore vaccine production plant that ruined 15 million doses of its COVID-19 vaccine and has moved to stop British drugmaker AstraZeneca Plc from utilizing the facility to avoid any future mistakes, senior federal health officials said on Saturday. The extraordinary decision, which was first reported by The New York Times, was put into action by the US Department of Health and Human Services and will allow the Emergent BioSolutions plant to focus on making the single-dose Johnson & Johnson COVID-19 vaccine.

Johnson & Johnson takes over COVID-19 vaccine production at Baltimore plant after 15 million doses were ruined

Merck

Pfizer

Do the math before you sell stocks based on proposed legislation.

How the Infrastructure Bill Will Raise Taxes on 3 Big Pharma Stocks

Moderna

They're working to target coronavirus strains of the future.

These 3 Vaccine Stocks May Be Post-Pandemic Winners

Mastercard

Palantir Technologies

These investments can make the most of your stimulus payment.

Got $1,400? Here's 3 Stocks to Buy and Hold for the Long Term

Johnson & Johnson has announced it is expanding its clinical trail to include adolescents aged 12 years old to 17 years old. "The COVID-19 pandemic has had a profound impact on adolescents, not just with the complications of the disease, but with their education, mental health, and wellbeing," said Paul Stoffels, vice chairman of the executive committee and chief scientific officer at Johnson & Johnson said in a statement. "It is vital that we develop vaccines for everyone, everywhere, to help combat the spread of the virus with the goal to return to everyday life."

Johnson & Johnson has begun testing its vaccine in adolescents

The answer depends on how today's vaccines handle the pandemic.

When Will Johnson & Johnson Start to Profit From Its COVID Vaccine?

During an interview on CNBC's Closing Bell on Thursday, Emergent BioSolutions CEO Bob Kramer said that it was "unfortunate," that a mixup occurred at its Baltimore facility producing Johnson & Johnson and Astrazeneca COVID-19 vaccines. "It's one batch," Kramer repeated when pressed on what exactly went wrong, not specifying or confirming whether that batch amounted to 15 million doses.

The CEO of the biotech firm that ruined Johnson & Johnson vaccine doses told CNBC 'it was one batch'

Proxy adviser Glass Lewis is recommending investors reject the nearly $30 million pay package for Johnson & Johnson Chief Executive Alex Gorsky, arguing that the healthcare company is shielding its top executives from the legal cost of poor business decisions.

Investors should reject J&J CEO pay package, proxy adviser Glass Lewis says

Shares of Emergent BioSolutions tumbled 7.44% in premarket trading on Thursday after Johnson & Johnson said the biopharmaceutical manufacturing plant spoiled 15 million COVID-19 vaccine doses.  Emergent BioSolutions is a contract manufacturer that produces both the Johnson & Johnson and AstraZeneca coronavirus vaccines.

Emergent BioSolutions tumbles 7% after J&J says it spoiled 15 million COVID-19 vaccine doses (EBS, JNJ, AZN)

Johnson & Johnson offers investors an island of safety -- JNJ stock is supported by a strong company and long-standing dividend. The post Johnson & Johnson: Ride Out the Tech Selloff with this Dividend King appeared first on InvestorPlace.

Johnson & Johnson: Ride Out the Tech Selloff with this Dividend King

Sanofi

Vaxart

Sometimes, the huge potential gains of small biotechs are worth the risk.

These 3 Stocks Will Make You A Fortune If They Succeed

One batch of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccines failed quality standards and are not fit for use, reported the New York Times on late Wednesday. What Happened: The company had found a problem with an ingredient used in the vaccine produced at Emergent Biosolutions Inc's (NYSE: EBS) site in Baltimore.

15M Doses Of JNJ COVID-19 Vaccine Batch Ruined After Ingredient Issues At Emergent Biosolutions' US Plant: NYT

The drugmaker didn't say how many doses were lost, and it wasn't clear how the problem would impact future deliveries.

Johnson & Johnson COVID-19 Vaccine Batch Fails Quality Standards

Company says it should still be on track to deliver 24 million vaccine doses through April.

Johnson & Johnson confirms vaccine production issues

Johnson & Johnson will have to temporarily halt shipping its coronavirus vaccine in the U.S. due to a mix-up at an Emergent Biosolutions plant. Late Wednesday, EBS stock tumbled.

J&J Covid Vaccine Shipments Halted As Plant Mix-Up Ruins 15 Million Doses

Johnson & Johnson Inc. on Wednesday acknowledged a batch of its COVID-19 vaccine produced by one of its manufacturing partners "did not meet quality standards," and said it will provide more experts to oversee production.

Johnson & Johnson admits batch of COVID-19 vaccine failed ‘quality standards'

The mixup will delay future shipments of the vaccine, according to the New York Times.

15 Million Johnson & Johnson Doses Reportedly Ruined Due Human Error At Baltimore Plant

This story is developing. Please check back for updates. Join the conversation about this story »

Roughly 15 million doses of the Johnson & Johnson vaccine were ruined because of a factory mixup

Disney

Walmart

These companies are poised for continued success far into the future.

Got $3000? Here Are 3 Stocks to Buy and Hold for the Long Term

Novartis

Roche Holding AG

Johnson & Johnson's (NYSE:JNJ) 2020 revenue topped all pharmaceutical companies, according to rankings published by Fierce Pharma.

Johnson & Johnson, Roche and Novartis Top in Pharma Sales

J&J's (JNJ) Pharma unit is performing above-market levels, helped by new drugs and label expansion of blockbuster drugs, Imbruvica, Darzalex & Stelara. Its COVID-19 vaccine is expected to contribute to sales growth.

J&J's (JNJ) Pharma Unit & COVID-19 Vaccine Key to 2021 Growth

Johnson and Johnson (NYSE: JNJ), through its Janssen Pharmaceutical NV unit, has entered into a deal with the African Vaccine Acquisition Trust that could order an additional 180 million doses of COVID-19 shot for a combined total of 400 million doses through 2022. JNJ will initially supply up to 220 million doses of the COVID-19 vaccine to the African Union's 55 member states from the third quarter of 2021.

News for Johnson & Johnson Stock (JNJ)